Evidence map›Paper›PMID 39407625›Full record

ArticleMolecules (Basel, Switzerland)2024

Synthesis, Anti-Cancer Activity, Cell Cycle Arrest, Apoptosis Induction, and Docking Study of Fused Benzo[

Zainab M Khoder, Mosaad S Mohamed, Samir M Awad, Amal F Gharib, Omnia Aly, Marwa Abd El-Fattah Khodair, Samar S Fatahala, Rania H Abd El-Hameed

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zainab M KhoderPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Helwan, Cairo 11795, Egypt.ORCID 0000-0002-5085-0850
Mosaad S MohamedPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Helwan, Cairo 11795, Egypt.
Samir M AwadPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Helwan, Cairo 11795, Egypt.
Amal F GharibDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.ORCID 0000-0001-8008-3368
Omnia AlyMedical Biochemistry Department, National Research Centre, Doki, P.O. Box 12622 Cairo, Egypt.ORCID 0000-0003-2754-6073
Marwa Abd El-Fattah KhodairPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Helwan, Cairo 11795, Egypt.ORCID 0000-0002-9954-140X
Samar S FatahalaPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Helwan, Cairo 11795, Egypt.ORCID 0000-0003-2957-8378
Rania H Abd El-HameedPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Helwan University, Helwan, Cairo 11795, Egypt.

Funding

Taif University, Saudi Arabia project number ( TU- DSPP- 2024- 54)
6 · The paper itself

Abstract

Breast cancer is the predominant form of cancer among women and ranks as the second most prevalent cancer globally, affecting both developed and less developed countries. Presently, accessible cancer treatment methods either employ recently created, secure, and efficient chemotherapeutic medications or directly target innovative pathways that cause apoptosis. One of the indirect strategies for treating this fatal illness has mostly depended on its essential role in cell cycle arrest and apoptosis induction, as well as the antagonistic interaction between the Bcl-2 and Mcl-1 proteins, in order to avert major health repercussions. We reported that newly synthesized fused chromenopyrimidines (

Indexed as

Antineoplastic AgentsApoptosisBreast NeoplasmsCell Cycle CheckpointsMolecular Docking SimulationPyrimidinesCell ProliferationFemaleHumansMCF-7 CellsMyeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsMyeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-bcl-2PyrimidinesapoptosisBcl-2/Mcl-1 assaychromenopyrimidinecytotoxicitymolecular dockingNCI-assay

Identifiers

PMID39407625
PMCPMC11478142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.